Showing papers in "Haematologica-the Hematology Journal in 2008"

Screening For Copy-Number Alterations And Loss-Of-Heterozygosity In Chronic Lymphocytic Leukemia - A Comparative Study Of Four Differently Designed, High Resolution Microarray Platforms

Abstract: Screening for gene copy‐number alterations (CNAs) has improved by applying genome‐wide microarrays, where SNP arrays also allow analysis of loss of heterozygozity (LOH). We here analyzed 10 chronic lymphocytic leukemia (CLL) samples using four different high‐resolution platforms: BAC arrays (32K), oligonucleotide arrays (185K, Agilent), and two SNP arrays (250K, Affymetrix and 317K, Illumina). Cross‐platform comparison revealed 29 concordantly detected CNAs, including known recurrent alterations, which confirmed that all platforms are powerful tools when screening for large aberrations. However, detection of 32 additional regions present in 2–3 platforms illustrated a discrepancy in detection of small CNAs, which often involved reported copy‐number variations. LOH analysis using dChip revealed concordance of mainly large regions, but showed numerous, small nonoverlapping regions and LOH escaping detection. Evaluation of baseline variation and copy‐number ratio response showed the best performance for the Agilent platform and confirmed the robustness of BAC arrays. Accordingly, these platforms demonstrated a higher degree of platform‐specific CNAs. The SNP arrays displayed higher technical variation, although this was compensated by high density of elements. Affymetrix detected a higher degree of CNAs compared to Illumina, while the latter showed a lower noise level and higher detection rate in the LOH analysis. Large‐scale studies of genomic aberrations are now feasible, but new tools for LOH analysis are requested. © 2008 Wiley‐Liss, Inc.

IFN-alpha PROMOTES PROLIFERATION OF DORMANT HSCS IN VIVO, MAKING THEM SUSCEPTIBLE TO ELIMINATION BY CHEMOTHERAPY

Abstract: Reference EPFL-CONF-160284View record in Web of Science Record created on 2010-11-30, modified on 2016-08-09

A Phase Ii International, Multicenter Study of Oral Panobinostat (lbh589) in Patients With Refractory Cutaneous T-cell Lymphoma (ctcl)

Abstract: This Phase II open-label multicenter study is enrolling CTCL patients (Stage IB–IVA), with mycosis fungoides (MF) or Sezary syndrome (SS), who have failed ≥2 prior systemic therapies, have adequate organ function and ECOG PS ≤2. Pts with significant cardiovascular abnormalities or QTcF >450 msec on screening ECG are excluded. Pts are stratified by either previous oral bexarotene (Group 1) or bexarotene-naive (Group 2) status; both following a Simon 2stage design. Panobinostat (20 mg) is administered orally on Days 1, 3, and 5 weekly until disease progression or intolerance. The primary endpoint is response rate measured by a composite of score derived from assessment of skin disease using modified Severity-Weighted Assessment Tool [mSWAT], and the evaluation of viscera and lymph nodes using CT. Intensive ECG monitoring for QTcF prolongation is performed.